Genetic Profiling Reveals Immunotherapy Potential for Rare Head and Neck Cancer
Dr. Yoshihito Kano's team found that immune checkpoint drugs helped only some patients with adenoid cystic carcinoma of the head and neck, and MYB gene changes may flag better responders.